Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

✍ Scribed by Nolte, F.; Höchsmann, B.; Giagounidis, A.; Lübbert, M.; Platzbecker, U.; Haase, D.; Lück, A.; Gattermann, N.; Taupitz, M.; Baier, M.; Leismann, O.; Junkes, A.; Schumann, C.; Hofmann, W. K.; Schrezenmeier, H.

• Book ID: 120656286
• Publisher: Springer
• Year: 2012
• Tongue: English
• Weight: 215 KB
• Volume: 92
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s00277-012-1594-z